Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
about
Liquid-solid phase-inversion PLGA implant for the treatment of residual tumor tissue after HIFU ablation.A novel nanoparticle formulation for sustained paclitaxel delivery.The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.Drug delivery systems: An updated reviewNanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovisNanovehicular intracellular delivery systems.Controlling lipid bioavailability through physicochemical and structural approaches.Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeabilityDevelopment of oral food-grade delivery systems: current knowledge and future challenges.Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.Nanocarrier-based interventions for the management of MDR/XDR-TB.Recent trends on hydrogel based drug delivery systems for infectious diseasesNanoparticle-based targeted gene therapy for lung cancer.Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization.Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.Effect of Crystalline Structure on Oxidation of Fish Oil in Stearin:Fish Oil Mixtures
P2860
Q30417350-284B3FF7-2E85-46E0-A6BC-310D956C90DBQ34293494-774CF76C-B3B8-410D-A961-B71946AE4324Q36252799-2BD7E311-AA45-4A9B-B6E7-84B0C135113FQ36300205-668BCAA1-1B6F-4585-BCDF-580234D5B054Q36583732-85265D84-A534-457E-A184-E4979930A5D2Q36804289-A17B3811-9C95-402A-8BE1-7AA3A49F8661Q37058812-FEA7B419-11B4-4BF3-A4B6-A3DEA7480A59Q37307707-787C9CBF-E91F-4EE5-8C5A-5EF7BB3967C7Q37412657-CAFD42C6-D0DB-428F-A592-331964276E5FQ37945066-57A61EA3-E936-40E9-AEB1-49E2C7F3E098Q37969743-991215AE-905B-4F35-A50E-6F6EDF09D062Q38095485-5447666A-5DB8-4F71-B676-75C33237723CQ38199540-0C43C4A1-74DF-4AFB-A94A-8AA5F3361F4AQ38375982-FBD6E2B0-126A-4DED-AD2C-4DF4414EEDF9Q38810357-DAA46F6A-9C3A-42A7-AF7D-0A2F830277C0Q38854207-7B85F715-1D11-40E1-A81C-9B53B66F0F9EQ39518383-AA9F644A-39A8-4373-B7F4-C22BAA93A13BQ39900986-224332A7-CBD4-409D-A554-0A4A642B84BAQ45968864-28F5BB13-6426-48B8-BD3A-B4C4CA4BB75BQ51543542-F8937840-EEF8-4084-AEB3-2258AA9B9CEAQ58874257-57253070-F8E0-4141-BBB6-43DA545FE66B
P2860
Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@ast
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@en
type
label
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@ast
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@en
prefLabel
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@ast
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@en
P1476
Physical chemical consideratio ...... ry--solid lipid nanoparticles.
@en
P2093
Paul M Bummer
P356
10.1615/CRITREVTHERDRUGCARRIERSYST.V21.I1.10
P577
2004-01-01T00:00:00Z